CagriSema, a drug that Novo had hoped would become the next generation weight-loss aid, failed to meet expectations in ...

The CEO of obesity drug manufacturer Novo Nordisk and heads of other Danish companies were expected to discuss preparations ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

The head of Ozempic maker Novo Nordisk A/S is among business executives who are meeting the Danish prime minister to discuss ...

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

A Scandinavian economic behemoth, Novo Nordisk is the highest-valued company in Europe at over $500 billion, which exceeds Denmark’s entire GDP. Ironically, Ozempic and Wegovy, as with many of ...

Eli Lilly's Tirzepatide Outshines Novo Nordisk's Semaglutide, Yet Brand Recognition Remains Strong for Novo's Products ...

Investing.com -- Bernstein analysts highlighted a more attractive valuation for Novo Nordisk (NYSE: NVO) following recent ...